| Metric | Value (₹ Cr) | vs Q2 FY25 |
|---|---|---|
| Revenue | 96.33 | 4.5% |
| Total Income | 98.08 | 4.9% |
| Expenditure | 92.38 | 2.1% |
| PBT | 5.70 | 92.5% |
| Net Profit | 4.00 | 68.0% |
| OPM | -3.80% | 2.98pp |
| NPM | 4.08% | 1.53pp |
| EPS | 0.82 | 67.3% |
Zim Laboratories Ltd Releases Q3 & 9M FY25 Earnings Presentation
11 Feb 2025 · 11 Feb 2025, 01:58 am
Summary
Zim Laboratories Ltd, a pharmaceutical company operating in various therapy segments and dosage forms, has released its Q3 and 9M FY25 earnings presentation. The company has an integrated business model with offerings across therapy areas and dosage forms, with a significant focus on R&D and innovation for product research and dossier creation. The company manufactures and supplies finished formulations, pre-formulation intermediates, oral thin films, and new innovative products.
Key Highlights
- 1
Q3 & 9M FY25 earnings presentation released
- 2
Company operates in the pharmaceutical sector
- 3
Integrated business model with offerings across therapy areas and dosage forms
- 4
Significant focus on R&D and innovation for product research and dossier creation
- 5
Manufacturing and supply of finished formulations, pre-formulation intermediates, oral thin films, and new innovative products
Management Comments
Not Provided
The presentation has been prepared by ZIM Laboratories Limited solely for information purposes and does not constitute an offer to sell or recommendation or solicitation of an offer to subscribe for or purchase any securities and nothing contained herein shall form the basis of any contract or commitment whatsoever.
Informational and educational content only. Not investment advice.